Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products

Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012

(2015) Roger Berg et al.   TRANSFUSION

Anti-A and anti-B haemagglutinin levels in intravenous immunoglobulins: Are they on the rise? A comparison of four different analysis methods and six products

(2013) C.L. Bellac et al.   BIOLOGICALS

Assessment of the ability of the Privigen®purification process to deplete thrombogenic factor XIa from plasma

(2013) M. Komenda et al.   VOX SANGUINIS

A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies

(2010) Karen Quillen et al.   TRANSFUSION

Acute Hemolysis After High-Dose Intravenous Immunoglobulin Therapy in Highly HLA Sensitized Patients

(2009) J. Kahwaji et al.   Clinical Journal of the American Society of Nephrology

Safety and Efficacy of Privigen®, a Novel 10% Liquid Immunoglobulin Preparation for Intravenous Use, in Patients with Primary Immunodeficiencies

(2008) Mark R. Stein et al.   JOURNAL OF CLINICAL IMMUNOLOGY